ArticleFrontiers in pharmacology2026
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Purpose: To systematically evaluate the protective effects of HUF extract on ALI and the pharmacological mechanisms involved. Methods: Using a lipopolysaccharide-induced mouse model of ALI, we investigated the effects of HUF on the intestinal microbiota of ALI mice via microbial sequencing, metabolomics sequencing, and fecal microbiota transplantation (FMT). We explored the targets and signaling pathways of HUF intervention using transcriptomics and network pharmacology methods and then validated our results using immunological experiments and polymerase chain reaction analysis (PCR). Results: HUF reduced lung indices and wet-dry ratios associated with pulmonary edema, alleviated inflammatory responses, and mitigated the severity of pulmonary pathological damage. HUF also increased the expression of intestinal tight junction protein (ZO-1), modulated the structure and relative abundance of the gut microbiota, and elevated the levels of certain short-chain fatty acids (SCFAs). FMT experiments confirmed that the HUF-mediated remodeling of the microbiota played a significant role in alleviating ALI. Transcriptomics and network pharmacology analyses suggested that the mechanism underling the interventional effect of HUF on ALI is related to inflammatory pathways. Immunological and PCR experiments further confirmed an association with the P38 mitogen-activated protein kinase (MAPK) pathway. Conclusion: HUF is associated with attenuation of ALI, correlating with modulation of the gut-lung axis and the inflammatory pathways, and HUF may be a candidate for the treatment of ALI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.